Vorozole

Research use only, not for human use.

Vorozole (R83842) is an orally active, potent, and selective nonsteroidal aromatase inhibitor.Vorozole exhibits antitumor activity in vivo and may be used in the study of breast cancer.

Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor. Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer.

Vorozole inhibits aromatase activity with an IC50s of 1.4 nM inFSH-stimulated rat granulosa cells.

Vorozole (0.8-1.25 mg/kg; Gavage; daily for 77 dayss) shows antitumor effect and increase the release of serum insulin-like growth factor (IGF)-1 and serum testosterone levels.Vorozole (p.o.; 5 days) dose-dependently reduced uterus weight and completely inhibited tumor aromatase in ovariectomized nude mice.Animal Model:Female Sprague-Dawley rats Dosage:0.08, 0.16, 0.31, 0.63 or 1.25 mg/kg Administration:Gavage; daily (starting at 43 days of age) for 77 days; given a single i.v. dose of methylnitrosourea (MNU) (50 mg/kg body wt) after 7 days Result:Caused a dose-dependent increase in body weight gain and decrease in cancer incidence, increased the insulin-like growth factor (IGF)-1, serum testosterone levels.

——

Metabolic Enzyme/Protease

P450

P450 | Aromatase

——

——

129731-10-8

324.77

C16H13ClN6

>98% (HPLC)

——

[C@@H](C=1C=C2C(=CC1)N=NN2C)(C3=CC=C(Cl)C=C3)N4C=NC=N4

——

(-20℃)

With Ice Pack

≥ 2 years